Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU

• DOI: 10.1093/jac/dkaa321
• Publication Date: 2020-07-08T19:09:55Z
• Authors: Zeno Pasquini; Roberto Montalti; Chiara Temperoni; Benedetta Canovari; Mauro Mancini; Michele Tempesta; Daniela Pimpini; Nicoletta Zallocco; Francesco Barchiesi
• Keywords: Charlson comorbidity index

Remdesivir is a prodrug with in vitro activity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Its clinical efficacy patients COVID-19 under mechanical ventilation remains to be evaluated.This study includes confirmed SARS-CoV-2 infection admitted the ICU of Pesaro hospital between 29 February and 20 March 2020. During this period, remdesivir was provided on compassionate use basis. Clinical characteristics outcome treated were collected retrospectively compared those hospitalized same time period.A total 51 considered, which 25 remdesivir. The median (IQR) age 67 (59-75.5) years, 92% men symptom onset 10 (8-12) days before admission ICU. At baseline, there no significant difference demographic characteristics, comorbidities laboratory values not Median follow-up 52 (46-57) days. Kaplan-Meier curves showed significantly lower mortality among who had been (56% versus 92%, P < 0.001). Cox regression analysis that Charlson Comorbidity Index only factor association higher (OR 1.184; 95% CI 1.027-1.365; = 0.020), while associated better survival 3.506; 1.768-6.954; 0.001).In rate high. beneficial effect survival.